Navigation Links
Using coxibs and NSAIDs to treat osteoarthritis
Date:8/13/2007

Mt Laurel, NJ 13 August 2007 - In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). The Editorial summarizes the outcomes of an international workshop organized by the Osteoarthritis Research Society International (OARSI) and the International COX-2 Study Group, held 2425 March 2007. The authors urge that an evidence-based approach must be taken when making recommendations to patients.

OA, the most common form of arthritis, is a major medical problem. It has been estimated that over 20 million Americans are afflicted with OA, and that number will rise to 40 million by the year 2020. Controversy now exists as to the safest and most efficacious way of treating the disease, particularly with respect to use of NSAIDs, both non-selective and selective (so-called COX-2 selective agents or coxibs). Adverse reactions related to the gastrointestinal tract, particularly with the non-selective NSAIDs, have been described; more recently, concerns have been expressed related to the cardiovascular system with both groups of agents.

A recent scientific statement from the American Heart Association (AHA) made recommendations with regard to the treatment of OA.1 A number of these recommendations are challenged in the Editorial2 in Osteoarthritis and Cartilage, with particular concern about their impact on appropriate use of these agents.

The Editorial questions the recommendation made in the AHA statement which described a stepped care approach to pharmacologic therapy for musculoskeletal diseases. The Editorial strongly recommends that several aspects of the AHA statement be reconsidered. For example, it urges that the AHA withdraw their non-evidence-based recommendations that high-dose aspirin be administered alone as a first line therapy for patients with chronic pain and arthritis.

Dr Roland W. Moskowitz, Professor of Medicine at Case Western Reserve University/University Hospitals of Cleveland, lead author of the Editorial comments, "Careful review of the pros and cons of using these agents, and the situations in which they are most safely and effectively used, is required to help us understand how best to take advantage of their availability".

The input by the OARSI/COX-2 International Study Group provides evidence-based background and guidance that will be of help to physicians, and to patients, in the use of these important commonly used agents.


'/>"/>
Contact: Ian Salusbury
ian.salusbury@elsevier.com
44-186-584-3000
Elsevier
Source:Eurekalert

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
3. Researchers urge caution in using ear tube surgery
4. Ulcer causing bug found in stored food
5. Using Stem Cells To Treat Incontinence In Women
6. Flu-Drugs Are Causing Resistance Across The World
7. Researchers at Cornell University as been reported using research fund by false claims
8. Relief to pregnant women using fertility drugs
9. The hazards of using disinfectant hand gel
10. Colon cancer risk linked to genes causing Hemochromatosis
11. Teens Misusing Nicotine-Replacement Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... ... from Greet, S.C., wants to offer people a new way to care for their feet. ... so I know the importance of proper foot care," he said. "In order to enable ... The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his or ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in ... Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, ... discusses strategies to prevent readmissions in light of the most recent programs at ...
(Date:3/29/2017)... Provo, Utah (PRWEB) , ... March 29, 2017 , ... ... an event to provide free screening colonoscopies to eligible individuals in the local community. ... and the U.S., but regular screenings can detect colon cancer while it is small, ...
(Date:3/29/2017)... ... , ... In the United States alone, up to 36% of primary brain ... metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to ... treatment options, the San Diego Gamma Knife Center offers a precision-medicine based ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up ... owners in creating legally-enforceable pet trusts for their canine companions. , Therilus, a ... their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... -- Boston Scientific Corporation (NYSE: BSX ) today ... privately-held Swiss structural heart company focused on minimally-invasive transcatheter ... The Symetis portfolio includes the ACURATE TA™ ... for use in the treatment of high-risk patients suffering ... sold in Europe and in ...
(Date:3/30/2017)... March 29, 2017 The new ... browse a comprehensive collection of company reports on ... and analysis of their activities in the healthcare industry. ... ... healthcare industry is going through a fundamental transformation globally-a ...
(Date:3/30/2017)... Research and Markets has announced the addition of ... By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, Services), ... 2025" report to their offering. ... The global hemodialysis and ... by 2025. Home-based dialysis treatment is ...
Breaking Medicine Technology: